Beat the AIDS epidemic Press for fair prices and better access to medicines.
|
|
- Nelson Arnold
- 8 years ago
- Views:
Transcription
1 Beat the AIDS epidemic Press for fair prices and better access to medicines. JUNE 2015 Globally, 35 million people are living with HIV. 22 million of them do not receive the treatment they need. The patent system forms an important barrier to access to HIV drugs, because it leads to unnecessary high prizes set by pharmaceutical companies. Today, at this defining point in the fight against AIDS, Aids Fonds and Artsen zonder Grenzen press for better access to medicines by fixing the current patent system.
2 Aids Fonds, Artsen zonder Grenzen and over 7,500 people call upon the Dutch Minister for Foreign Trade and Development to: Put ending the negative effects of the current patent system on access to medication for people living with HIV on the agenda during the Dutch EU Presidency in 2016; Press for fair trade agreements and treaties of the Netherlands and the EU, in which access to affordable and generic medicines for low- and middle-income countries is guaranteed; Provide legal assistance to low- and middle-income countries to stimulate them to make use of TRIPS-flexibilities; Take a leading role in exploring an alternative model for the development of new medicines, that stimulates pharmaceutical innovation but prevents patents and high prices, in close cooperation with the Dutch Minister of Health, Welfare and Sport.
3 What is wrong with the current patent system? HIV medication (ART 1 ) can like products, services, ideas or knowledge be patented, as they are the result of research and innovation. The basic framework for patent regulations (what can be patented, for how long and under what conditions) is set by the World Trade Organization (WTO). All WTO member states agreed on TRIPS 2 in 1994, protecting the owners of patents, including medicines. The TRIPS agreement obliges each WTO member country to grant at least a 20-year patent on new products. This minimum of 20 years of patent protection applies to all processes and products and does not distinct whether or not the products are life-saving medicines or luxury items. Medicines particularly newer medicines needed for second and third line HIV treatment 3 are expensive because of strong intellectual property protections that result in high prizes. However, in some circumstances, (developing) countries have the possibility to legally circumvent patents and import or produce cheap, generic medicines 4, the so-called TRIPS-flexibilities, enforced in the Doha declaration in This 2001 Declaration states that the patent regime should protect public health and promote access to medicines for everyone. The flexibility -measures that governments can take include: l Compulsory licenses: governments give a license to produce, sell, or import a generic medicine, without the consent of the patent owner. l Parallel importing: governments import medicines from countries where these are sold by the patent holder against lower prices. l Patent opposition: governments refuse to grant a patent, including for lack of novelty, or to revoke a patent. As a result, generic medicines are allowed on the market. But countries that have attempted to bring down the prices of medicines have come under economic and political pressure from richer countries and the pharmaceutical industry. While the global community has repeatedly made commitments to secure affordable medicines for all, this promise runs counter to the prevailing economic and trade interests that view medicines as investments and commodities from which to extract maximum profit. The importance of generic antiretroviral drugs. Since 2001, global political mobilization cleared the way for competitive production of generic versions of widely patented medicines. Thanks to this generic competition, prices for antiretroviral treatment were drastically reduced from 7,500 per year for a patented combination of antiretroviral drugs in 2001, to 60 a year for a generic combination nowadays. This meant being able to put 13 million people on treatment in low- and middle-income countries in the past 15 years. However, this same success is now under threat, asking for new global political mobilization.
4 The number of people that needs access to newer, patented and therefore more expensive HIV-drugs is progressively increasing (e.g. because regimens to treat HIV are changing to more effective and less toxic drugs, or because the number of people that do not respond to first-line regimes is increasing). However, most low- and middle-income countries are not able to pay for these drugs, leaving patients with no or sub-optimal treatment. New bilateral trade agreements e.g. between the EU and low or middle income countries often include provisions that forbid the use of TRIPSflexibilities (so-called TRIPS-plus provisions), prohibiting the use of generics. Today, every year 1.5 million people still die of AIDS, while life-saving treatment is available: many countries cannot afford the HIV treatment for people living with HIV; TRIPS-plus provisions in trade agreements undermine access to affordable medicines; in some (middle income) countries, health budgets are spent on medicine purchase only; people living with HIV are more vulnerable to other diseases, such as tuberculosis and hepatitis. TB is the leading cause of death of people living with HIV. Even when countries are able to afford buying the needed medicines, effects are severe as the prices of medication are higher than they should be, and the limited budget of these countries cannot be spent on other parts of the health sector. We are at a pivotal point in the global fight against AIDS. If we want to beat AIDS, we need to fix the patent system. The human impact of this lack of flexibility in the patent system. In Morocco, the cost of third-line raltegravir, darunavir and etravirine represents 13% of the total HIV-medicines budget allocated by the department of health and the Global Fund. However, this treatment regime is used by only 0.2% of people living with HIV on treatment (only 11 people!). India is known as the developing country pharmacy. It has played a crucial role in the development of the generic drug industry. It is estimated that more than 90% of the global supply of HIV drugs come from India. However, India must now abide the TRIPS agreements and must grant 20-year exclusivity to drugs that are considered to be the inventions of pharmaceutical players. Fortunately, India s patent law is still quite strict on granting patents. Only real inventions can be patented, leaving room for the production of many generic HIV medicines. But this situation is likely to change as a result of current free trade treaty negotiations. The EU has been negotiating with India globally the largest producer of affordable and generic medicines about a free trade treaty. There are concerns that this new agreement will obstruct India to continue its role as pharmacy of the world. Current agreements are under negotiation with Brazil, Thailand, and the Philippines.
5 How can you fix the patent system and make life-saving medicines accessible for all people living with HIV? There are proven solutions to guarantee universal access to drugs not only to those who live in the poorest countries. These solutions focus on generic competition, such as compulsory licensing and patent opposition. We need expanded use of these existing flexibilities in patent law, especially for low- and middle-income countries, to lower medicine prices and to increase access to treatment. Moreover, we need to work towards alternative models that not only guarantee access to existing medicines, but that stimulates real medical innovation that is highly needed to develop new treatments for HIV and tuberculosis. Aids Fonds, Artsen zonder Grenzen, 7,500 people in the Netherlands and millions of people worldwide ask you to: Put ending the negative effects of the current patent system on access to medication for people living with HIV on the agenda during the Dutch EU Presidency in 2016; Press for fair trade agreements and treaties of the Netherlands and the EU, in which access to affordable and generic medicines for low- and middle-income countries is guaranteed; Provide legal assistance to low- and middle-income countries to stimulate them to make use of TRIPS-flexibilities; Take a leading role in exploring an alternative model for the development of new medicines, that stimulates pharmaceutical innovation but prevents patents and high prices, in close cooperation with the Dutch Minister of Health, Welfare and Sport. Beat the AIDS epidemic and fix the patent system! 1 Antiretroviral Treatment 2 TRIPS: Trade Related Aspects of Intellectual Property Rights an agreement between members of the World Trade Organization about intellectual property. 3 HIV is a virus that easily develops resistance against antiretroviral treatment. If this happens, the medicines the patient started with (first line) are not effective any more, and the patient has to switch to another combination of drugs, called second line. If this regimen fails as well, a third line combination has to be prescribed. In general, medicines used in second and third line combinations are newer, patented drugs, and therefore much more expensive. 4 A generic drug is a pharmaceutical product, completely interchangeable with a branded product, but manufactured without a license from the innovator company. Generic drugs normally costs a fraction of the price of the branded product. Generics should not be confused with counterfeit medicine: drugs that are deliberately and fraudulently mislabeled with respect to identity and/or source. Sources: Londeix, P. (2014). Supply and demand: Why drug prices and trade barriers are blocking drug access and what activist scan do about it. Extract from AIDS Today: Tell no lies, claim no easy victories (2014) published by the International HIV/AIDS Alliance. Zaidi, S. Access challenges for HIV treatment among People Living with HIV and Key Populations in Middle-Income Countries. Policy brief, October t Hoen, E et al (2011). Driving a decade of change HIV/ AIDS, patents and access to medicines for all. Journal of the International AIDS Society. Dey, S. (2015). Fears over EU plan for strict drug patent regime. India Times, 14 April 2015.
6 Organizations that support this petition: Netherlands Aids Foundation East-West Amref flying doctors Choice COC Cordaid dance4life GNP+ Hiv Vereniging Nederland ICCO Coöperatie International Civil Society Support KNCV Tuberculosis Foundation Mainline Nederlandse Vereniging van Hiv behandelaren Rutgers Simavi STOP AIDS NOW! TAMPEP Wemos International AGIHAS (LAT) AIDS Action Europe (GER) Aids Hilfe Wien (AUS) AIDS-Support (SER) ARAS (ROM) ArchImeDeS (CZE) Demetra (LIT) ECUO (ROM) European AIDS Treatment Group (BEL) HOPS (MAC) Medico-Psychotherapeutic Center Labyrinth (KOS) National AIDS Trust (UK) International HIV/AIDS Alliance (UK) LILA (ITA) Projecte dels NOMS-Hispanosida (SPA) Sensoa (BEL) SKUC (SLO) UNAIDS Acknowledgements Michaël Kensenhuis, Jorrit Kabel, Anne Dankert, Katrien Coppens, Lucia Broms For more information please contact Michaël Kensenhuis at Aids Fonds:
THE POTENTIAL IMPACT OF FREE TRADE AGREEMENTS ON PUBLIC HEALTH
UNDP, UNAIDS ISSUE BRIEF 2012 THE POTENTIAL IMPACT OF FREE TRADE AGREEMENTS ON PUBLIC HEALTH The Potential Impact of Free Trade Agreements on Public Health UNDP, UNAIDS UNAIDS / JC2349E (English original,
More informationIntellectual Property and Access to HIV/AIDS Treatment Case Studies
Intellectual Property and Access to HIV/AIDS Treatment Case Studies Recent TRIPS-related developments in the rest of the world In developing countries Until now, India, Brazil and Thailand have been among
More informationACCESS TO AFFORDABLE TREATMENT FOR HIV/AIDS: THE ISSUES
ACCESS TO AFFORDABLE TREATMENT FOR HIV/AIDS: THE ISSUES AIDS Law Unit Legal Assistance Centre July, 2002 INTRODUCTION Although there is currently no cure for HIV/Aids, treatment has, however, been developed
More informationSIXTY-SEVENTH WORLD HEALTH ASSEMBLY. Agenda item 12.3 24 May 2014. Hepatitis
SIXTY-SEVENTH WORLD HEALTH ASSEMBLY WHA67.6 Agenda item 12.3 24 May 2014 Hepatitis The Sixty-seventh World Health Assembly, Having considered the report on hepatitis; 1 Reaffirming resolution WHA63.18,
More informationThe Medicines Patent Pool Understanding the Patent Status of Antiretroviral Drugs. Ellen t Hoen Medicines Patent Pool
The Medicines Patent Pool Understanding the Patent Status of Antiretroviral Drugs Ellen t Hoen Medicines Patent Pool WHO-WIPO-WTO Symposium February 18, 2011 The International Context WTO Doha Declaration
More informationDublin Declaration. on Partnership to fight HIV/AIDS in Europe and Central Asia
Dublin Declaration on Partnership to fight HIV/AIDS in Europe and Central Asia Against the background of the global emergency of the HIV/AIDS epidemic with 40 million people worldwide living with HIV/AIDS,
More informationTACD RECOMMENDATIONS ON HEALTH CARE AND INTELLECTUAL PROPERTY AND EUROPEAN COMMISSION SERVICES RESPONSES
TRANSATLANTIC CONSUMER DIALOGUE WASHINGTON MEETING, 10-12 FEBRUARY 2000 TACD RECOMMENDATIONS ON HEALTH CARE AND INTELLECTUAL PROPERTY AND EUROPEAN COMMISSION SERVICES RESPONSES The Commission Services
More informationEROSION OF EXCLUSIVE MARKETING RIGHTS- BOON FOR THE PHARMACEUTICAL SECTOR
IPR & TECHNOLOGY BULLETIN EROSION OF EXCLUSIVE MARKETING RIGHTS- BOON FOR THE PHARMACEUTICAL SECTOR Contents Introduction...2 1. What is EMR?...2 2. Provisions of TRIPS...3 2.1 TRIPS and India s compliance...3
More informationSADC PHARMACEUTICAL PROGRAMME SADC PHARMACEUTICAL BUSINESS PLAN 2007-2013
SADC PHARMACEUTICAL PROGRAMME SADC PHARMACEUTICAL BUSINESS PLAN 2007-2013 SADC SECRETARIAT 27 TH JUNE 2007 ACRONYMS AIDS : Acquired Immunodeficiency Syndrome Antiretroviral ARV : Antiretroviral cgmp :
More informationAids Fonds funding for programmes to prevent HIV drug resistance
funding for programmes to prevent HIV drug resistance Call for proposals July 2012 Page 1 van 10 grants@aidsfonds.nl Documentnumber 20120719/JKA/RAP Universal Access Lifting barriers to universal access
More informationGENEVA STANDING COMMITTEE ON THE LAW OF PATENTS. Fourteenth Session Geneva, January 25 to 29, 2010 PROPOSAL FROM BRAZIL *
WIPO SCP/14/7. ORIGINAL: English DATE: January 20, 2010 E WORLD INTELLECTUAL PROPERT Y O RGANI ZATION GENEVA STANDING COMMITTEE ON THE LAW OF PATENTS Fourteenth Session Geneva, January 25 to 29, 2010 PROPOSAL
More informationThe Prize Fund for HIV/AIDS
The Prize Fund for HIV/AIDS A New Paradigm for Supporting Sustainable Innovation and Access to New Drugs for AIDS: De-Linking Markets for Products from Markets for Innovation May 26, 2011 Introduction
More informationImporting Western Style, Exporting Tragedy: Changes in Indian Patent Law and Their Impact on AIDS Treatment in Africa
Northwestern Journal of Technology and Intellectual Property Volume 6 Issue 1 Fall Article 8 Fall 2007 Importing Western Style, Exporting Tragedy: Changes in Indian Patent Law and Their Impact on AIDS
More informationTraining Course on the Public Health Implications of Multilateral Trade Agreements, University of Lausanne (14-18 June 2004)
Training Course on the Public Health Implications of Multilateral Trade Agreements, University of Lausanne (14-18 June 2004) TRIPS Agreement and Public Health Cecilia Oh Department of Essential Drugs and
More informationTrade Related Aspects of Intellectual Property Rights (TRIPS): Protecting patents or patients?
Trade Related Aspects of Intellectual Property Rights (TRIPS): Protecting patents or patients? Anand Bhat, MS II University of Texas Medical Branch, Galveston, TX 2008 Ellen R. Shaffer, PhD MPH, Co-Director
More informationContact: Your Name. Email address. FOR IMMEDIATE RELEASE November 6, 2006. Page 1 of 2
Q October 16, 2006 Contact: Your Name Phone number Email address FOR IMMEDIATE RELEASE November 6, 2006 Students Across North America Call for Universities to Stop Abetting Access-to-Medicines Crisis in
More informationRE: Transatlantic Business Concerns about Indian Government IP Policies
The Honorable Michael Froman Assistant to the President and Deputy National Security Adviser for International Economic Affairs The White House Washington, DC 20504 USA Ambassador Ron Kirk U.S. Trade Representative
More informationThe Pharmaceutical Industry and the Patent System. Bruce Lehman 1 President, International Intellectual Property Institute
The Pharmaceutical Industry and the Patent System Bruce Lehman 1 President, International Intellectual Property Institute 1 2003 1 Executive Summary Patents are exclusive property rights in intangible
More informationPharmaceutical Counterfeiting: Issues, Trends, Measurement
Pharmaceutical Counterfeiting: Issues, Trends, Measurement Harvey Bale, Ph.D. DG, International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) President, Pharmaceutical Security Institute
More informationAccess to medicines should not be a luxury for the rich but a right for all.
Access to medicines should not be a luxury for the rich but a right for all. Ellen F. M. t Hoen 1 Introduction Infectious diseases kill 17 million people each year, and more than ninety percent of these
More informationAFRICAN UNION ROADMAP: PROGRESS IN THE FIRST YEAR
AFRICAN UNION ROADMAP: PROGRESS IN THE FIRST YEAR Update on progress to implement the African Union Roadmap on Shared Responsibility and Global Solidarity for AIDS, TB and Malaria Response in Africa (2012
More informationWHO Medicines Strategy. Countries at the core 2004 2007. World Health Organization
WHO Medicines Strategy Countries at the core 2004 2007 World Health Organization Expanding access to essential medicines Scaling up access to essential medicines especially for HIV/AIDS, tuberculosis and
More informationAre We There Yet? Taking "TRIPS" to Brazil and Expanding Access to HIV/AIDS Medication
Brooklyn Journal of International Law Volume 33 Issue 3 SYMPOSIUM: Corporate Liability for Grave Breaches of International Law Article 10 2008 Are We There Yet? Taking "TRIPS" to Brazil and Expanding Access
More informationPublic health at risk
OXFAM MEDIA BRIEFING 09/2012 July 2012 Public health at risk US trade policy endangers access to affordable anti-retroviral medicines Background Less than a year after US Secretary of State Hillary Clinton
More informationPATENT ISSUES & LOCAL PHARMACEUTICAL PRODUCTION IN GHANA. By Kwasi Poku Boateng QUALITY MANAGEMENT CONSULTANT
PATENT ISSUES & LOCAL PHARMACEUTICAL PRODUCTION IN GHANA By Kwasi Poku Boateng QUALITY MANAGEMENT CONSULTANT International Conference on Local Pharmaceutical Production in Africa, Cape Town, April 4-6,
More informationParallel Importation: Economic and social welfare dimensions
Parallel Importation: Economic and social welfare dimensions Frederick M. Abbott June 2007 Prepared for the Swiss Agency for Development and Cooperation (SDC) 2007 International Institute for Sustainable
More informationHow does the NHS buy HIV Drugs?
The April 2011 announcement of changes to HIV drugs purchasing arrangements in London highlighted the direct impact of National Health Service (NHS) drugs procurement budgets and processes on individual
More informationMINISTERIAL CONFERENCE
MINISTERIAL CONFERENCE FIGHTING AGAINST HIV/AIDS TEN YEARS AFTER THE DUBLIN DECLARATION: LEAVING NO ONE BEHIND ENDING AIDS IN EUROPE Rome, 27-28 November 2014 Ministry of Health 1 Italian Presidency of
More informationHealth and Health Care in India Policy implications for Europe
Health and Health Care in India Policy implications for Europe David Taylor Professor of Pharmaceutical and Public Health Policy University College London School of Pharmacy Dr Jennifer Gill Research Fellow
More informationPROMOTING ACCESS AND MEDICAL INNOVATION: INTERSECTIONS BETWEEN PUBLIC HEALTH, INTELLECTUAL PROPERTY AND TRADE
PROMOTING ACCESS AND MEDICAL INNOVATION: INTERSECTIONS BETWEEN PUBLIC HEALTH, INTELLECTUAL PROPERTY AND TRADE Joint study by the WHO, WIPO and WTO Secretariats Outline and overview The WHO, WIPO and the
More informationAccess to Medicines and Vaccines: Implications of Intellectual Property Protection and Trade Agreements
WORLD HEALTH ORGANIZATION REGIONAL OFFICE FOR SOUTH-EAST ASIA 23rd Meeting of Health Ministers of Countries of SEAR Colombo, Sri Lanka, 4-5 September 2005 SEA/HMM/Meet.23/5 18 August 2005 Access to Medicines
More informationEnsuring Safety and Access
Ensuring Safety and Access Peter Maybarduk Public Citizen pmaybarduk@citizen.org April 2014 or Thinking Usefully About Counterfeits Peter Maybarduk Public Citizen pmaybarduk@citizen.org April 2014 Counterfeit
More informationTOWARDS MORE COHERENCE BETWEEN INTERNATIONAL TRADE AND THE RIGHTS OF THE CHILD
TOWARDS MORE COHERENCE BETWEEN INTERNATIONAL TRADE AND THE RIGHTS OF THE CHILD I. International cooperation, international trade and the Convention on the Rights of the Child Under the Convention on the
More informationSOUTH-WEST EUROPE 21
21 SOUTH-WEST EUROPE SOUTH-WEST EUROPE Croatia, Cyprus, Greece, Italy, Malta, Portugal, Slovenia, Spain Access to medicines and medical devices in Mediterranean EU Member States As members of the EU, all
More informationCompetition policy brief
Issue 2015-3 June 2015 ISBN 978-92-79-38783-8, ISSN: 2315-3113 Competition policy brief Occasional discussion papers by the Competition Directorate General of the European Commission The Interchange Fees
More informationDOHA+10 TRIPS FLEXIBILITIES AND ACCESS TO ANTIRETROVIRAL THERAPY: LESSONS FROM THE PAST, OPPORTUNITIES FOR THE FUTURE
Key Highlights UNAIDS TECHNICAL BRIEF 2011 DOHA+10 TRIPS FLEXIBILITIES AND ACCESS TO ANTIRETROVIRAL THERAPY: LESSONS FROM THE PAST, OPPORTUNITIES FOR THE FUTURE Doha+10 TRIPS flexibilities and access to
More informationAccess to affordable essential medicines 1
35 Access to affordable essential medicines 1 Target 8e In cooperation with pharmaceutical companies, provide access to affordable essential drugs in developing countries. Target 8e of the Millennium Development
More informationUp to $402,000. Insight HIV. Drug Class. 1.2 million people in the United States were living with HIV at the end of 2011 (most recent data).
HIV Background, new developments, key strategies Drug Class Insight INTRODUCTION Human Immunodeficiency Virus (HIV) is the virus that can lead to Acquired Immunodeficiency Syndrome, or AIDS. No safe and
More informationEye on the Ball. Medicine regulation not IP enforcement can best deliver quality medicines. www.oxfam.org. 143 Oxfam Briefing Paper 2 February 2011
143 Oxfam Briefing Paper 2 February 2011 Eye on the Ball Medicine regulation not IP enforcement can best deliver quality medicines www.oxfam.org An AIDS patient holding drugs provided through the Thai
More informationSouth Africa s IP Policy
South Africa s IP Policy Way Forward? Benefits of Substantive Examination for Pharmaceutical Patent Claims IP Forum, South Africa, 2013 Doctors Without Borders/ Medecins Sans Frontieres MSF, is an independent
More informationPoor access to HCV treatment is undermining Universal Access A briefing note to the UNITAID Board
Poor access to HCV treatment is undermining Universal Access A briefing note to the UNITAID Board The growing crisis of HIV/HCV coinfection It is estimated that 4-5 million people living with HIV (PLHIV)
More informationXVIIth International Aids Conference, Mexico City
XVIIth International Aids Conference, Mexico City 5 August 2008 Parliamentary Briefing on HIV/AIDS: parliamentarians as partners in the fight against HIV. Prof. Dr. Marleen Temmerman, Senator, Belgian
More informationTuberculosis OUR MISSION THE OPPORTUNITY
Tuberculosis OUR MISSION Guided by the belief that every life has equal value, the Bill & Melinda Gates Foundation works to help all people lead healthy, productive lives. Our Global Health Program is
More informationHIV/AIDS Drug Donations
Briefing Paper 4 June 2001 Australian Federation of AIDS Organisations (AFAO) PO Box 51 Newtown NSW 2042 Australia HIV/AIDS Drug Donations Throughout 2000 and 2001, the issue of global access to HIV/AIDS
More informationTRIPS transition period extensions for least-developed countries
issue Brief 2013 TRIPS transition period extensions for least-developed countries Empowered lives. Resilient nations. Health burdens in least-developed countries the challenge of access In confronting
More informationAmerican Academy of Physician Assistants
950 North Washington Street Alexandria, VA 22314-1552 703/836-2272 Fax 703/684-1924 TESTIMONY OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS SUBMITTED TO THE DEPARTMENT OF HEALTH AND HUMAN SERVICES TASK
More informationSTATISTICAL ISSUES STRUCTURE OF PRESENTATION
COUNTERFEITING AND PIRACY: WIPO/OECD EXPERT MEETING ON MEASUREMENT AND STATISTICAL ISSUES Bernardita Escobar - Advisor to Minister of the Economy and Energy- Chile STRUCTURE OF PRESENTATION 1 Determining
More informationHealth Alert Communications Communication in Life Sciences
Sorry, the document you sought has been removed. However, the attached pages may be of some interest. Otherwise, for more information, please visit our web site or the links to Amazon.com provided below:
More informationProposed National e health authority (NeHA) Blueprint by Dr. Rahul Sinha
Proposed National e health authority (NeHA) Blueprint by Dr. Rahul Sinha In my view the proposed NeHA should be having the following objective:- To provide effective health care at affordable price to
More informationWhy Are Drugs So Expensive? Learning About the Drug Development Process
Why Are Drugs So Expensive? Page 1 of 92 Why Are Drugs So Expensive? Learning About the Drug Development Process written by: Ann Newman Seventh Street Development Group This product is for your Personal
More informationBlood-clotting disorders XARELTO Identifying genuine products of Bayer HealthCare
Blood-clotting disorders XARELTO Identifying genuine products of Bayer HealthCare Product presentation, packaging design, and selected security features Imprint Bayer HealthCare AG 51368 Leverkusen Germany
More informationCORRUPTION IN THE HEALTH SECTOR
CORRUPTION IN THE HEALTH SECTOR Based on Executive Summary and Foreword by Mary Robison, Corruption and Health: Global Corruption Report, 2006 Transparency International, Feb.2006 Contents Introduction
More informationDave Burrows Director
Dave Burrows Director Effects of drug policy on HIV transmission What is the Comprehensive Package of Services for People Who Inject Drugs (PWID) What is an enabling environment for addressing HIV among
More informationSummary. Request for Advice
Summary Health Council of the Netherlands. Vaccination of young children against tuberculosis. The Hague: Health Council of the Netherlands, 2011; publication no. 2011/04 Even though the global prevalence
More informationGlobal Update on HIV Treatment 2013: Results, Impact and Opportunities
June 2013 Global Update on HIV Treatment 2013: Results, Impact and Opportunities WHO/UNAIDS/UNICEF v2 Outline Results: Progress towards Global Targets - Antiretroviral treatment - Prevention of mother-to-child
More informationJanssen Global Public Health: HIV Medicines Access & Partnerships Program APRIL 2014. Julius Bustamante, Pajaros
Julius Bustamante, Pajaros Artwork from Hospital Audiences, Inc. (HAI), a nonprofit organization that inspires healing, growth and learning through access to the arts for the culturally underserved. Janssen
More informationAccess to Medicines, Patent Information and Freedom to Operate
TECHNICAL SYMPOSIUM Access to Medicines, Patent Information and Freedom to Operate Summary and key issues TRILATERAL SYMPOSIA On 18 February 2011, the World Health Organization (WHO), the World Intellectual
More informationDEVELOPING WORLD HEALTH PARTNERSHIPS DIRECTORY
DEVELOPING WORLD HEALTH PARTNERSHIPS DIRECTORY OVER 250 HEALTH PARTNERSHIPS THAT MAKE A DIFFERENCE TO PEOPLE S LIVES The global health community needs to overcome both new and current challenges in the
More informationGroup insurance. Generic drugs. Their positive effect on your wallet
Group insurance Generic drugs Their positive effect on your wallet A wise choice Prescription drugs have a couple of things in common: they re designed to heal us or make us feel better, and most of them
More informationSituation report on the status of HIV/TB/HCV/OST programs in Donetsk and Luhansk oblasts (as of 28.01.2015 )
International HIV/AIDS Alliance in 5 Dymytrova St., building 10-A, 9-th floor, 03680, Kyiv, Tel.: (+380 44) 490-5485 Fax: (+380 44) 490-5489 Е-mail: office@aidsalliance.org.ua www.aidsalliance.org.ua Situation
More informationAccess to Affordable HIV/AIDS Drugs: The Human Rights Obligations of Multinational Pharmaceutical Corporations
Fordham Law Review Volume 71 Issue 3 Article 15 2002 Access to Affordable HIV/AIDS Drugs: The Human Rights Obligations of Multinational Pharmaceutical Corporations Lissett Ferreira Recommended Citation
More informationNew Frontiers Old Cowboys: A Consumer Perspective on ehealth Initiatives
New Frontiers Old Cowboys: A Consumer Perspective on ehealth Initiatives Nicola Ballenden The move to an efficient, patient-focused health system as outlined by John Dwyer and the Australian Health Reform
More informationSYLLABUS REALISING THE INTERNATIONAL RIGHT TO HEALTH. Course Description and Purpose
SYLLABUS Course Description and Purpose REALISING THE INTERNATIONAL RIGHT TO HEALTH Taught by the former UN Special Rapporteur on Health and a practising Senior Counsel in the Supreme Court of India, Anand
More informationWIPO TRAINING OF TRAINERS PROGRAM ON EFFECTIVE INTELLECTUAL PROPERTY ASSET MANAGEMENT BY SMALL AND MEDIUM-SIZED ENTERPRISES (SMEs)
WIPO TRAINING OF TRAINERS PROGRAM ON EFFECTIVE INTELLECTUAL PROPERTY ASSET MANAGEMENT BY SMALL AND MEDIUM-SIZED ENTERPRISES (SMEs) IP Law and Administration in the State of Qatar by Malik Al-Kammaz Saba
More informationSNAP: Telling Our Stories, Heroin Assisted- Treatment and Advocacy
SNAP: Telling Our Stories, Heroin Assisted- Treatment and Advocacy NPA PARTICPANT SUPPORT and ADVOCACY In January 2011, Dave Murray with support from Ann Livingston organized a group of participants from
More informationFOREWORD. Member States in 2014 places patients and communities at the heart of the response. Here is an introduction to the End TB Strategy.
FOREWORD We stand at a crossroads as the United Nations move from the 2015 Millennium Development Goals (MDGs) to the Sustainable Development Goals (SDGs) for 2030. Integral to this transition, the world
More informationSession 6: Enhancing Pharmaceutical Procurement. Michael Gabra
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationBuilding a Serialization Compliance Management System. Lewis Kontnik, Director Brand Protection Amgen Inc. (Oct. 2012)
Building a Serialization Compliance Management System Lewis Kontnik, Director Brand Protection Amgen Inc. (Oct. 2012) About Amgen Amgen discovers, develops, manufactures, and delivers innovative human
More informationFramework for rapid assessment of the pharmaceutical sector in a given country
Framework for rapid assessment of the pharmaceutical sector in a given country Prepared for Flagship Course (Health) Glossary: EU GLP GMP HIF IMS INN MOH NGO OEBIG OECD OTC PER R&D Rx TRIPS VAT WHO European
More informationACTA - State of Play. Karel De Gucht. European Commissioner for Trade
Karel De Gucht European Commissioner for Trade ACTA - State of Play 1st Exchange of Views with the Committee for International Trade of the European Parliament Brussels, 29 February 2012 Professor Moreira,
More informationGLOBAL ACCESS LICENSING FRAMEWORK
GLOBAL ACCESS LICENSING FRAMEWORK Every university-developed technology with potential for further development into a drug, vaccine, or medical diagnostic should be licensed with a concrete and transparent
More informationGlobal Economy Journal
Global Economy Journal Volume 5, Issue 4 2005 Article 1 Perspectives on the WTO Doha Development Agenda Multilateral Trade Negotiations Overview: Perspectives on the WTO Doha Development Agenda Multilateral
More informationHIV DRUG RESISTANCE EARLY WARNING INDICATORS
HIV DRUG RESISTANCE EARLY WARNING INDICATORS World Health Organization indicators to monitor HIV drug resistance prevention at antiretroviral treatment sites June 2010 Update ACKNOWLEDGEMENTS The preparation
More informationA Public Health Approach to Hepatitis C using Direct Acting Antivirals (DAAs) A summary of DNDi s proposed five-year Hepatitis C project
A Public Health Approach to Hepatitis C using Direct Acting Antivirals (DAAs) A summary of DNDi s proposed five-year Hepatitis C project 4 September 2015 Executive Summary According to the World Health
More informationStatement Of. For. U.S. House of Representatives Energy and Commerce Committee Subcommittee on Oversight and Investigations.
Statement Of The National Association of Chain Drug Stores For U.S. House of Representatives Energy and Commerce Committee Subcommittee on Oversight and Investigations Hearing on: Counterfeit Drugs: Fighting
More informationHealth insurance systems in The Netherlands
Health insurance systems in The Netherlands March 22, 2003 Authors: Fons Bertens, Head of Statistics Department of The Netherlands Health Insurance Institution Jan Bultman, Lead Health Specialist, World
More informationVII. IMPACT ON THE HEALTH SECTOR
VII. IMPACT ON THE HEALTH SECTOR The HIV/AIDS epidemic has posed and will continue to pose tremendous challenges to the health systems of the developing countries, especially in the most severely affected
More informationMilitarism and HIV/AIDS: The Deadly Consequences for Women. Background paper by Women's International League for Peace and Freedom
Militarism and HIV/AIDS: The Deadly Consequences for Women Background paper by Women's International League for Peace and Freedom UN General Assembly Special Session on HIV/AIDS June, 2001 It is known
More informationPrescription for Life:
Prescription for Life: Take action to help children living with HIV The vast majority of children living with HIV around the world lack access to HIV testing and treatment. We can do something about that.
More informationCorporate Social Responsibility (CSR)
Today, many of the world s remaining natural resources can be found on or in indigenous peoples territories. This poses great threats to their lands, natural environment and their well being, and often
More informationThe role of private sector in health care: challenging the myths. Catherine Olier 25 October 2012
The role of private sector in health care: challenging the myths Catherine Olier 25 October 2012 Health in developing countries KEY NUMBERS: 6.9 million children > 5 died in 2011, early 800 every hour
More informationCOMPULSORY LICENSING FOR PUBLIC HEALTH: A GUIDE AND MODEL DOCUMENTS FOR IMPLEMENTATION OF THE DOHA DECLARATION PARAGRAPH 6 DECISION
COMPULSORY LICENSING FOR PUBLIC HEALTH: A GUIDE AND MODEL DOCUMENTS FOR IMPLEMENTATION OF THE DOHA DECLARATION PARAGRAPH 6 DECISION Frederick M. Abbott and Rudolf V. Van Puymbroeck ii TABLE OF CONTENTS
More informationStrengthening Policies on the Harmful Use of Alcohol, Gender-Based Violence and Infectious Disease
Strengthening Policies on the Harmful Use of Alcohol, Gender-Based Violence and Infectious Disease A joint UNDP, WHO, IOGT, & FORUT initiative Dudley Tarlton dudley.tarlton@undp.org SVRI Forum, September
More informationHow To Achieve Your Vision Of Ending Of Aids
SETTING MILESTONES STRATEGY 214-217 TABLE OF CONTENTS Introduction 3 1. Our strategy map 5 2. Our vision 7 3. HIV and STIs in a changing world 9 4. Our added value 16 5. Our objectives 17 6. Our values
More informationPROPOSAL by Bangladesh, Barbados Bolivia, and Suriname. Prize Fund for Development of Low-Cost Rapid Diagnostic Test for Tuberculosis. Date: 09.04.
PROPOSAL by Bangladesh, Barbados Bolivia, and Suriname Prize Fund for Development of Low-Cost Rapid Diagnostic Test for Tuberculosis Executive Summary Date: 09.04.15 The governments of Bangladesh, Barbados,
More informationIntegrated care in the Netherlands
Katja van Vliet and Dick Oudenampsen Integrated care in the Netherlands Keynote presentation Integrated Care Systems Invitational conference during the Dutch EU-Presidency 18-19 November 2004 The Hague
More informationACCESS CHALLENGES FOR HIV TREATMENT
ACCESS CHALLENGES FOR HIV TREATMENT Among People Living with HIV and Key Populations in Middle-Income Countries POLICY BRIEF // OCTOBER 2013 Acronyms ACTA AIDS ART ARV EPA EU FTA HAART HIV ICESCR IP MDG
More informationColombia's decision on compulsory license & access to HIV/AIDS medicine LPV/r
Bogotá. June 3, 2009. Colombia's decision on compulsory license & access to HIV/AIDS medicine LPV/r The Colombian ministry of health has decided not to declare access to HIV/AIDS medicine lopinavir + ritonavir
More informationTRIPS AND COMPULSORY LICENSING: INCREASING PARTICIPATION IN THE MEDICINES PATENT POOL IN THE WAKE OF AN HIV/AIDS TREATMENT TIMEBOMB
TRIPS AND COMPULSORY LICENSING: INCREASING PARTICIPATION IN THE MEDICINES PATENT POOL IN THE WAKE OF AN HIV/AIDS TREATMENT TIMEBOMB ABSTRACT Significant progress has been made in recent decades to increase
More informationBRIEF ON THE TREATMENT OF INTELLECTUAL DECLARATION: MANDATED NEGOTIATIONS PROPERTY IN THE DOHA WTO MINISTERIAL AND REVIEWS
C ENTER FOR I NTERNATIONAL E NVIRONMENTAL L AW BRIEF ON THE TREATMENT OF INTELLECTUAL PROPERTY IN THE DOHA WTO MINISTERIAL DECLARATION: MANDATED NEGOTIATIONS AND REVIEWS BY DAVID VIVAS EUGUI 1 FEBRUARY,
More informationPhilippines Philippines Philippinen. Report Q202. in the name of the Philippine Group by Rogelio NICANDRO
Philippines Philippines Philippinen Report Q202 in the name of the Philippine Group by Rogelio NICANDRO The impact of public health issues on exclusive patent rights Questions I) Analysis of current law
More informationKey Messages. Health Economics & Management
Key Messages Health Economics & Management General World Health Summit 2011: Today s Science Tomorrow s Agenda The World Health Summit is the annual conference held by the M8 Alliance of the Academic Health
More informationAid, trade, diplomacy and law enforcement
Aid, trade, diplomacy and law enforcement A Dutch view on reducing deforestation in supply chains of agricultural commodities. Rob Busink, Nature and Biodiversity Department Transatlantic Dialogue, 23-24
More informationISSUE BRIEF. Trans-Pacific Partnership: Curbing Access to Medicines Now and in the Future. Summary. May 2015. Overview
The Foundation for AIDS Research May 2015 ISSUE BRIEF Trans-Pacific Partnership: Curbing Access to Medicines Now and in the Future Overview The Trans-Pacific Partnership (TPP) is currently being negotiated
More informationThe future agenda for development cooperation: voices of Dutch society
The future agenda for development cooperation: voices of Dutch society Contribution prepared for the High Level Panel on the Post 2015 development agenda - March 2013 Prepared by NCDO, in cooperation with
More informationPalliative care is a patient-centred approach that
PALLIATIVE CARE AND ACCESS TO MEDICATIONS FOR PAIN TREATMENT CLAIRE MORRIS, INTERNATIONAL ADVOCACY AND PROGRAMMES MANAGER, WORLDWIDE PALLIATIVE CARE ALLIANCE, LONDON, UK The World Health Organization (WHO)
More informationENFORCEMENT OF IP RIGHTS IN THE DIGITAL ENVIRONMENT CONCERNS, CHALLENGES AND ACTIONS REQUIRED FOR THE PROTECTION OF THE SINGLE MARKET.
ENFORCEMENT OF IP RIGHTS IN THE DIGITAL ENVIRONMENT CONCERNS, CHALLENGES AND ACTIONS REQUIRED FOR THE PROTECTION OF THE SINGLE MARKET GRUR Workshop Brussels March 7, 2007 Michael Keplinger* Overview: 1.
More information298.015) UC 6:30 8:20 PM
Course Description: This course is an in depth review of the history, authorizing statute and regulatory authority of US FDA and the influence and impact of FDA on science and health policy. Drug development,
More informationThe Republic of Estonia Health Insurance Act
The Republic of Estonia Health Insurance Act Passed on 12 June 1991 Entered into force 1 January 1992 (RT 1991, 23,272) Amended by the following Acts: 04.05.1992, 22.03.1994, 18.03.1997,09.12.1998, 18.02.1999,
More information